KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (Diluted Average) (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Shares Outstanding (Diluted Average) data on record, last reported at $45.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 2.6% year-over-year to $45.0 million; the TTM value through Dec 2025 reached $45.0 million, down 2.6%, while the annual FY2025 figure was $45.0 million, 2.6% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $45.0 million in Q4 2025 per PCRX's latest filing, down from $45.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $52.5 million in Q2 2022 and bottomed at $45.0 million in Q4 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $48.1 million, with a median of $46.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 15.1% in 2022, then dropped 11.5% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $45.6 million in 2021, then rose by 1.99% to $46.5 million in 2022, then grew by 11.69% to $52.0 million in 2023, then decreased by 11.03% to $46.2 million in 2024, then decreased by 2.6% to $45.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $45.0 million in Q4 2025, $45.7 million in Q3 2025, and $45.5 million in Q2 2025.